Tango Therapeutics (TNGX) Current Deferred Revenue (2020 - 2025)
Historic Current Deferred Revenue for Tango Therapeutics (TNGX) over the last 6 years, with Q2 2025 value amounting to $23.4 million.
- Tango Therapeutics' Current Deferred Revenue fell 124.22% to $23.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $23.4 million, marking a year-over-year decrease of 124.22%. This contributed to the annual value of $17.6 million for FY2024, which is 3136.74% down from last year.
- Per Tango Therapeutics' latest filing, its Current Deferred Revenue stood at $23.4 million for Q2 2025, which was down 124.22% from $19.5 million recorded in Q1 2025.
- In the past 5 years, Tango Therapeutics' Current Deferred Revenue registered a high of $34.0 million during Q1 2023, and its lowest value of $15.6 million during Q3 2024.
- In the last 5 years, Tango Therapeutics' Current Deferred Revenue had a median value of $25.8 million in 2021 and averaged $25.7 million.
- In the last 5 years, Tango Therapeutics' Current Deferred Revenue skyrocketed by 3591.35% in 2023 and then tumbled by 4236.85% in 2024.
- Tango Therapeutics' Current Deferred Revenue (Quarter) stood at $26.0 million in 2021, then grew by 22.17% to $31.8 million in 2022, then dropped by 19.26% to $25.7 million in 2023, then plummeted by 31.37% to $17.6 million in 2024, then soared by 32.67% to $23.4 million in 2025.
- Its Current Deferred Revenue was $23.4 million in Q2 2025, compared to $19.5 million in Q1 2025 and $17.6 million in Q4 2024.